The network pharmacology results revealed that the key targets of active STT components, namely GM2A, REN, MMP12, RBP4, and S100A9, are primarily associated with psoriasis, potentially serving as the basis for the therapeutic effectiveness of STT. Here, GM2A is linked to psoriasis.